MAP3K8 and skin squamous cell carcinoma: Our research extends prior studies showing clinical efficacy of gefitinib and lapatinib in cSCC treatment and provides mechanistic evidence supporting EGFR as a primary therapeutic target in Tpl2-deficient tumors [33,34].